SMOLDERING MULTIPLE MYELOMA: TREATMENT VERSUS OBSERVATION

被引：0
作者：
Patriarca, F. [1 ,2 ]
Musto, P. [3 ,4 ]
机构：
[1] Univ Udine, Div Hematol, Dept Med Area, Udine, Italy
[2] Azienda Sanit Univ Friuli Cent, Cellular Therapies Unit, Udine, Italy
[3] Aldo Moro Univ, Sch Med, Dept Emergency & Organ Transplantat, Bari, Italy
[4] AOU Consorziale Policlin, Unit Hematol & Stem Cell Transplantat, Bari, Italy
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 10期
关键词：
CRITERIA;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：197 / 199
页数：3
相关论文
共 16 条
  • [1] Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
    Jagannath, Sundar
    Laubach, Jacob
    Wong, Ellice
    Stockerl-Goldstein, Keith
    Rosenbaum, Cara
    Dhodapkar, Madhav
    Jou, Ying-Ming
    Lynch, Mark
    Robbins, Michael
    Shelat, Suresh
    Anderson, Kenneth C.
    Richardson, Paul G.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (04) : 495 - 503
  • [2] Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study
    Kazandjian, Dickran
    Hill, Elizabeth
    Morrison, Candis
    Dew, Alexander
    Korde, Neha
    Mailankody, Sham
    Manasanch, Elisabet E.
    Kwok, Mary L.
    Bhutani, Manisha
    Tageja, Nishant
    Zhang, Yong
    Carpenter, Ashley
    Epstein, Monica
    Emanuel, Michael
    Lu, Crystal
    Braylan, Raul C.
    Calvo, Katherine R.
    Choyke, Peter
    Dulau-Florea, Alina
    Mena, Esther
    Lindenberg, Liza
    Maric, Irina
    Patel, Nisha
    Stetler-Stevenson, Maryalice
    Wang, Hao-Wei
    Yuan, Constance M.
    Steinberg, Seth M.
    Figg, William D.
    Roschewski, Mark
    Landgren, Ola
    [J]. BLOOD, 2020, 136
  • [3] Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data
    Kumar, Shaji K.
    Abdallah, Al-Ola
    Badros, Ashraf Z.
    Laplant, Betsy
    Dhakal, Binod
    Alsina, Melissa
    Abonour, Rafat
    Rosenbaum, Cara A.
    Bensinger, William I.
    Bhutani, Manisha
    Jakubowiak, Andrzej
    Kim, Erica
    Durie, Brian G. M.
    [J]. BLOOD, 2020, 136
  • [4] Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
    Kyle, Robert A.
    Remstein, Ellen D.
    Therneau, Terry M.
    Dispenzieri, Angela
    Kurtin, Paul J.
    Hodnefield, Janice M.
    Larson, Dirk R.
    Plevak, Matthew F.
    Jelinek, Diane F.
    Fonseca, Rafael
    Melton, Lee Joseph, III
    Rajkumar, S. Vincent
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (25) : 2582 - 2590
  • [5] Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
    Landgren, C. Ola
    Chari, Ajai
    Cohen, Yael C.
    Spencer, Andrew
    Voorhees, Peter
    Estell, Jane A.
    Sandhu, Irwindeep
    Jenner, Matthew W.
    Williams, Catherine
    Cavo, Michele
    van de Donk, Niels W. C. J.
    Beksac, Meral
    Moreau, Philippe
    Goldschmidt, Hartmut
    Kuppens, Steven
    Bandekar, Rajesh
    Clemens, Pamela L.
    Neff, Tobias
    Heuck, Christoph
    Qi, Ming
    Hofmeister, Craig C.
    [J]. LEUKEMIA, 2020, 34 (07) : 1840 - 1852
  • [6] Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
    Lionetti, Marta
    Da Via, Matteo C.
    Albano, Francesco
    Neri, Antonino
    Bolli, Niccolo
    Musto, Pellegrino
    [J]. CANCERS, 2021, 13 (13)
  • [7] Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
    Liu, Chia-Jen
    Ghobrial, Irene M.
    Bustoros, Mark
    Reyes, Kaitlen
    Hornburg, Kalvis
    Badros, Ashraf Z.
    Vredenburgh, James J.
    Boruchov, Adam
    Matous, Jeffrey V.
    Caola, Aaron
    Rivotto, Bradley
    Savell, Alexandra
    Henrick, Patrick
    Paba-Prada, Claudia E.
    Schlossman, Robert L.
    Laubach, Jacob
    Rosenblatt, Jacalyn
    Yee, Andrew J.
    Nadeem, Omar
    Maegawa, Rodrigo O.
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Bhutani, Manisha
    Cappuccio, Joseph
    Berrios, Brianna
    Noonan, Kimberly
    Zavidij, Oksana
    Mouhieddine, Tarek H.
    Boehner, Cody J.
    Neuse, Carl-Jannes
    Salem, Karma Ziad
    Reidy, Mairead
    Park, Jihye
    Agius, Michael
    Rahmat, Mahshid
    Manier, Salomon
    Bhutani, Divaya
    Zonder, Jeffrey A.
    Munshi, Nikhil
    Auclair, Daniel
    Anderson, Kenneth
    Richardson, Paul
    [J]. BLOOD, 2018, 132
  • [8] Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
    Lonial, Sagar
    Jacobus, Susanna
    Fonseca, Rafael
    Weiss, Matthias
    Kumar, Shaji
    Orlowski, Robert Z.
    Kaufman, Jonathan L.
    Yacoub, Abdulraheem M.
    Buadi, Francis K.
    O'Brien, Timothy
    Matous, Jeffrey V.
    Anderson, Daniel M.
    Emmons, Robert V.
    Mahindra, Anuj
    Wagner, Lynne I.
    Dhodapkar, Madhav V.
    Rajkumar, S. Vincent
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (11) : 1126 - +
  • [9] Mailankody S, 2019, J CLIN ONCOL, V37
  • [10] A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
    Manasanch, Elisabet E.
    Jagannath, Sundar
    Lee, Hans C.
    Patel, Krina K.
    Graham, Connor
    Kaufman, Gregory P.
    Thomas, Sheeba K.
    Iyer, Swami
    Mailankody, Sham
    Korde, Neha
    Amini, Behrang
    Lin, Pei
    Berkova, Zuzana
    Weber, Donna M.
    Lei, Feng
    Lendvai, Nikoletta
    Hildebrandt, Michelle
    Neelapu, Sattva S.
    Orlowski, Robert Z.
    Landgren, Ola
    [J]. BLOOD, 2019, 134
12